ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2197

Malignant Atrophic Papulosis (MAP) Complicating Connective Tissue Diseases (CTDs)

Aixa Toledo-Garcia1,2, Lee S. Shapiro2,3,4 and Jessica F. Farrell2,3,5, 1Rheumatology, The Center for Rheumatology, Albany, NY, 2Steffens Scleroderma Center, Saratoga Springs, NY, 3The Center for Rheumatology, Albany, NY, 4Albany Medical College, Albany, NY, 5Pharmacy Practice, Albany College of Pharmacy & Health Sciences, Albany, NY

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Degos Disease and connective tissue diseases

  • Tweet
  • Email
  • Print
Session Information

Title: Miscellaneous Rheumatic and Inflammatory Diseases

Session Type: Abstract Submissions (ACR)

Background/Purpose

Malignant Atrophic Papulosis (MAP) is a rare vasculopathy of unknown etiology commonly presenting with cutaneous lesions, but can progress to multisystem disease with a fatal outcome. MAP has been reported in the setting of other CTDs. Currently, there is a limited understanding of the association between CTDs and overlapping MAP. We theorize that MAP can present independent or complicating a vasculopathic CTD.

Methods

We performed a retrospective review on approximately 200 MAP cases obtained through a PubMed literature search, personal experience and communications with treating physicians worldwide. Cases were then analyzed for overlapping CTDs and further stratified for factors associated with disease outcomes.

Results

Of the 200 MAP cases, we identified 33 with an overlapping CTD diagnosis.  These included: 11 SLE, 1 chronic cutaneous lupus erythematosus (CCLE), 3 SSc, 8 DM, 1 amyopathic DM, 6 APL syndrome (including patients positive for antibodies) 1 undifferentiated CTD, 1 granulomatous polyangiitis, and 1 RA. Patients with systemic MAP had fatal outcomes. Patients positive for APL antibodies with cutaneous MAP have survived but patients with APL syndrome and MAP have died. DM patients given steroids have died. In the setting of SSc there are two females who are alive and one male who died of fulminant SSc. Both females were on treprostinil for pulmonary hypertension.

Conclusion

MAP complicating CTD represents a challenging picture diagnostically and therapeutically. The presence of MAP may be a marker of more severe microvascular disease in those with SSc and DM and may be associated with worse prognosis because of concurrent steroid use. Steroids have been associated with increase risk of GI perforations and death. We believe MAP can present in the setting of a CTD in both cutaneous only and systemic forms. Histologically lupus and MAP can have similar findings but are not the same disease. MAP is not a systemic vasculitis but in its initial stages can present with an inflammatory infiltrate that later changes to the characteristic dermal necrosis and atrophic dermis with non-inflammatory endarterial thrombotic occlusion, leading to wedge-shaped skin necrosis, sclerosis and mucinosis. When MAP affects the CNS, the CNS pathology could have a perivascular lymphocytic infiltrate like a vasculitis, but MAP is not a vasculitis and seems to respond very poorly to steroids.  Early intervention of systemic MAP can be lifesaving.


Disclosure:

A. Toledo-Garcia,
None;

L. S. Shapiro,
None;

J. F. Farrell,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/malignant-atrophic-papulosis-map-complicating-connective-tissue-diseases-ctds/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology